- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00482521
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
A Phase I, Open-Label Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety Profile of CC-4047 in Subjects With Advanced Solid Tumors
RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of CC-4047 in patients with advanced refractory solid tumors.
Secondary
- Assess the safety of this drug in these patients.
- Assess the antitumor activity of this drug in these patients.
- Determine the effect of this drug on fetal hemoglobin levels in these patients.
OUTLINE: This is a open-label, uncontrolled, nonrandomized, dose-escalation, multicenter study.
- Treatment phase (course 1): Patients receive oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period.
Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).
Patients with no clinical evidence of progressive disease or DLT after course 1 continue study treatment during the extension phase. Patients who develop a DLT during course 1 may continue study treatment at the discretion of the investigator.
- Extension phase: Patients continue taking CC-4047 at their assigned cohort dose as in course 1. Patients who tolerate a treatment-phase dose higher than the MTD continue treatment at the MTD. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection at baseline and periodically during study to evaluate fetal hemoglobin levels.
After completion of study treatment, patients are followed at 28 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
-
Cleveland, Ohio, United States, 44106-5065
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically confirmed advanced solid tumor
Refractory disease
- Patients must have been offered and refused OR received and failed prior treatment with all standard or approved therapies for the malignancy
- Measurable or evaluable disease as confirmed by radiographic or clinical evidence
- No curative therapy available
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 3 months
- ANC > 1,500/mm³
- Platelet count > 75,000/mm³
- Hemoglobin ≥ 9.0 g/dL
- Creatinine ≤ 2.0 mg/dL
- AST and ALT < 3 times upper limit of normal
- Not pregnant
- No nursing during and for ≥ 28 days after completion of study treatment
- Two negative pregnancy tests required
- Fertile women must use effective double-method contraception for ≥ 28 days before, during, and for ≥ 28 days after completion of study treatment
- Men must use a latex condom during sexual contact with fertile females during and for ≥ 28 days after completion of study treatment, even if a prior successful vasectomy was performed
- Stable neurological exam
- No serious medical condition or psychiatric illness that would preclude study participation
- No prior desquamating rash or allergic reaction ≥ grade 2 while taking thalidomide, lenalidomide, or structurally related compounds
- No peripheral neuropathy ≥ grade 2
- No active infection
- No uncontrolled hyper- or hypocalcemia, glycosemia, or thyroidism
PRIOR CONCURRENT THERAPY:
- No prior CC-4047
- More than 28 days since prior cytotoxic chemotherapy (42 days for nitrosoureas)
- At least 14 days since prior therapeutic radiotherapy
- More than 14 days since prior thalidomide, lenalidomide, or structurally related compounds
- More than 14 days since prior biological response modifier therapy
- Concurrent radiotherapy to treat pain associated with existing bone lesions during the extension phase of the study allowed provided < 10% of bone marrow is irradiated
- Concurrent systemic steroids for control of CNS primary tumor and/or metastases symptoms allowed provided dose is stable or decreasing AND patient is also taking low-dose aspirin and/or other platelet-active, anti-thrombotic medication during and for 30 days after completion of study treatment
- No other concurrent chemotherapy or immunotherapy
- No other concurrent investigational agents
- No concurrent hematopoietic growth factors during the treatment phase of the study
- No other concurrent anticancer agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CC-4047
|
Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period.
Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose
Time Frame: after initial 28 day cycle
|
To determine the maximum tolerated dose (MTD) of daily CC-4047 in an initial 28-day cycle (21 days of CC-4047 followed by 7 days of no therapy) in subjects with advanced solid tumors (Cohort A).
|
after initial 28 day cycle
|
Dose-limiting toxicity
Time Frame: Courses repeat every 28 days for up to 24 months in the absence of unacceptable toxicity.
|
Courses repeat every 28 days for up to 24 months in the absence of unacceptable toxicity.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor response as assessed by RECIST criteria
Time Frame: after every 2 courses (28 days/ course)
|
after every 2 courses (28 days/ course)
|
Duration of response
Time Frame: Courses repeat every 28 days for up to 24 months in the absence of disease progression.
|
Courses repeat every 28 days for up to 24 months in the absence of disease progression.
|
Fetal hemoglobin levels as assessed thereafter
Time Frame: at baseline and every 28 days thereafter
|
at baseline and every 28 days thereafter
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Matthew M. Cooney, MD, Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
- Principal Investigator: Robert Dreicer, MD, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE4Y06 (Other Identifier: Case Comprehensive Cancer Center)
- P30CA043703 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on CC-4047
-
CelgeneCompletedPrimary Myelofibrosis | MPN-associated MyelofibrosisUnited States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
-
Yale UniversityCelgene CorporationCompletedMultiple MyelomaUnited States
-
University of ArkansasCelgeneCompletedMultiple MyelomaUnited States
-
CelgeneTerminatedSystemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, SystemicUnited States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
-
University of UlmActive, not recruitingPrimary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MFGermany
-
The Cleveland ClinicCompletedHereditary Hemorrhagic Telangiectasia | Idiopathic Vascular EctasiaUnited States
-
CelgeneCompleted
-
Washington University School of MedicineCompleted
-
Celgene CorporationCompletedSafety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)Prostate CancerUnited States
-
CelgeneCompletedMultiple MyelomaBelgium, United Kingdom, Italy, Germany, Sweden, Denmark, Norway, Spain